专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130266584A1 METHODS AND COMPOSITIONS FOR TREATING CELIAC DISEASE 审中-公开
标题翻译：治疗CELIAC疾病的方法和组合
公开(公告)号：US20130266584A1
公开(公告)日：2013-10-10
申请号：US13695349
申请日：2011-04-29
申请人： Detlef Schuppan , Yvonne Junker , Towia Libermann , Simon T. Dillon
发明人： Detlef Schuppan , Yvonne Junker , Towia Libermann , Simon T. Dillon
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/16 , C07K2317/76
摘要： The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.
摘要翻译：本发明的特征在于治疗与由α淀粉酶抑制剂CM3，α淀粉酶抑制剂0.19（0.19），CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或其衍生物相关的先天免疫应答相关的胃肠道疾病 α淀粉酶抑制剂0.53（0.53）。为此，本发明的特征在于药物组合物，包括中和CM3，0.19，CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53的抗体，含有CM3，0.19， CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53蛋白，使用口服TLR4抑制剂来阻断所述α-淀粉酶抑制剂的作用，用于鉴定CM3，0.19，CM1， CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53含量，以及用于诊断与CM3，0.19，CM1，CM2，CMa，CMd，CM16，CMb相关的病症的受试者的测定，CMX1 / CMX3，CMX2和/或0.53触发先天免疫应答。

2. 发明申请

US20100120754A1 IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES 审中-公开
标题翻译：鉴定和使用小分子调节转录因子功能和治疗转录因子相关疾病
公开(公告)号：US20100120754A1
公开(公告)日：2010-05-13
申请号：US12436685
申请日：2009-05-06
申请人： Peter Oettgen , Alan Rigby , Towia Libermann
发明人： Peter Oettgen , Alan Rigby , Towia Libermann
IPC分类号： A61K31/54 , C40B30/02 , A61K31/36 , A61K31/522 , A61K31/17 , A61K31/13 , C07D279/06 , C07D473/00 , C07D317/44 , C07C273/00 , C07C211/00
CPC分类号： G16C20/60 , G16B35/00
摘要： The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor.
摘要翻译：本发明涉及鉴定能够调节转录因子功能的小分子候选试剂的方法，使得该目标蛋白质下游的靶转录因子和/或蛋白质的功能/表达包括使用计算机高通量筛选小分子文库通过独特的转录因子和/或在药效基团内定义的DNA描述符来选择性鉴定其靶向和破坏转录因子-DNA界面的能力的候选小分子/试剂的对接，然后测试/评价上述鉴定的候选试剂通过一种或多种体外测定来调节转录因子功能的能力，包括表达该靶蛋白和/或靶转录因子下游的蛋白质。

3. 发明授权

US08741557B2 Predicting graft rejection 有权
标题翻译：预测移植排斥反应
公开(公告)号：US08741557B2
公开(公告)日：2014-06-03
申请号：US10545198
申请日：2004-02-17
申请人： Terry B. Strom , Towia Libermann , Asher Schachter
发明人： Terry B. Strom , Towia Libermann , Asher Schachter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , G06F19/00 , Y02A90/26
摘要： Prognostic methods useful in assessing patients who have received a transplant and reagents that can be used to carry out those methods are provided. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, i.e., variables associated with the donor, the recipient and/or the graft. The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes as “inflammatory”, “immune” or “cytoprotective”). Surprisingly, the levels of gene expression could predict the occurrence of DGF, AR, and the quality of later graft function even when analyzed shortly after (e.g., after vascular anastomosis and tissue reperfusion). We also found that clinical parameters available at the time of transplantation correlate with decreased graft health and can be considered in combination with gene expression to evaluate a patient's risk for an adverse outcome.
摘要翻译：提供了可用于评估接受移植的患者和可用于执行这些方法的试剂的预后方法。本发明部分基于我们对肾同种异体移植物中的基因表达和临床参数的分析，即与供体，受体和/或移植物相关的变量。可以评估的基因包括介导炎症，免疫激活和细胞死亡的编码剂（我们可以将这些基因称为“炎症”，“免疫”或“细胞保护”）。令人惊讶的是，即使在（例如在血管吻合术和组织再灌注后）分析后，基因表达的水平可以预测DGF，AR的发生以及晚期移植物功能的质量。我们还发现移植时可用的临床参数与移植物健康状况有关，可以与基因表达相结合，以评估患者的不良结局风险。

4. 发明申请

US20080113386A1 PREDICTING DIABETIC NEPHROPATHY 审中-公开
标题翻译：预测糖尿病
公开(公告)号：US20080113386A1
公开(公告)日：2008-05-15
申请号：US12018945
申请日：2008-01-24
申请人： Ravi Thadhani , S. Karumanchi , Towia Libermann
发明人： Ravi Thadhani , S. Karumanchi , Towia Libermann
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/347 , G01N2800/52
摘要： The invention relates to methods and compositions for identifying subjects who are predisposed to having diabetic nephropathy (DN).
摘要翻译：本发明涉及用于识别倾向于具有糖尿病性肾病（DN）的受试者的方法和组合物。

5. 发明申请

US20070111245A1 Predicting diabetic nephropathy 审中-公开
标题翻译：预测糖尿病肾病
公开(公告)号：US20070111245A1
公开(公告)日：2007-05-17
申请号：US11595562
申请日：2006-11-09
申请人： Ravi Thadhani , S. Karumanchi , Towia Libermann
发明人： Ravi Thadhani , S. Karumanchi , Towia Libermann
IPC分类号： C12Q1/68 , G01N33/53 , C12M3/00
CPC分类号： C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/347 , G01N2800/52
摘要： The invention relates to methods and compositions for identifying subjects who are predisposed to having diabetic nephropathy (DN).
摘要翻译：本发明涉及用于识别倾向于具有糖尿病性肾病（DN）的受试者的方法和组合物。

6. 发明申请

US20110071142A1 IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES 审中-公开
标题翻译：鉴定和使用小分子调节转录因子功能和治疗转录因子相关疾病
公开(公告)号：US20110071142A1
公开(公告)日：2011-03-24
申请号：US12727740
申请日：2010-03-19
申请人： Peter Oettgen , Alan C. Rigby , Towia Libermann
发明人： Peter Oettgen , Alan C. Rigby , Towia Libermann
IPC分类号： C40B30/02 , A61K31/136 , A61K31/36 , A61K31/52 , A61K31/5415 , A61K31/167 , A61K31/17 , A61K31/428 , A61K31/225 , A61K31/37 , A61K31/443 , C07D317/58 , C07D473/38 , C07D279/16 , C07C233/29 , C07C275/40 , C07C321/26 , C07D317/68 , C07D417/12 , C07C233/33 , C07C271/28 , C07D407/06 , C07D405/12 , C07D317/66 , C07C275/38 , A61P1/00 , A61P29/00 , A61P17/06 , A61P27/02 , A61P35/00
CPC分类号： G16C20/60 , G16B35/00
摘要： The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g., a compound of Formula XI), their pharmaceutically acceptable salts and to methods of using said compounds as described herein.
摘要翻译：本发明涉及鉴定能够调节转录因子功能的小分子候选试剂的方法，使得靶标蛋白质下游的靶转录因子和/或蛋白质的功能/表达包括使用计算机高通量筛选小分子文库通过独特的转录因子和/或在药效基团内定义的DNA描述符来选择性鉴定其靶向和破坏转录因子-DNA界面的能力的候选小分子/试剂的对接，然后测试/评价上述鉴定的候选试剂通过一种或多种体外测定来调节转录因子功能的能力，包括表达该靶蛋白和/或靶转录因子下游的蛋白质。本发明还涉及本文所述的各种化合物（例如式XI的化合物），其药学上可接受的盐以及使用本文所述的所述化合物的方法。

7. 发明申请

US20070122806A1 Predicting graft rejection 有权
标题翻译：预测移植排斥反应
公开(公告)号：US20070122806A1
公开(公告)日：2007-05-31
申请号：US10545198
申请日：2004-02-17
申请人： Terry Strom , Towia Libermann , Asher Schachter
发明人： Terry Strom , Towia Libermann , Asher Schachter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , G06F19/00 , Y02A90/26
摘要： The present invention features prognostic methods useful in assessing patients who have received a transplant and reagents, optionally packaged as kits or organized as arrays, that can be used to carry out those methods. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, such as the age of the donor. The clinical parameters include one or more variables associated with the recipient (e.g., the recipient's age and/or race); one or more variables associated with the graft (e.g., whether the graft is obtained from a living donor or a cadaver and the ischemic time); and variables associated with the donor (e.g., the donor's age and/or race). The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes below as “inflammatory”, “immune” or “cytoprotective”). Surprisingly, we found that the levels of gene expression could predict the occurrence of DGF, AR, and the quality of later graft function even when analyzed shortly after the transplant was performed (e.g., shortly after vascular anastomosis and tissue reperfusion). We also found that clinical parameters available at the time of transplantation correlate with decreased graft health and can be considered in combination with gene expression to evaluate a patient's risk for an adverse outcome.
摘要翻译：本发明具有用于评估已经接受移植的患者的预后方法和可以用于实施这些方法的试剂，可选地包装为试剂盒或组织为阵列。本发明部分基于我们对肾同种异体移植物中基因表达和临床参数的分析，如供体的年龄。临床参数包括与接收者相关联的一个或多个变量（例如，接收者的年龄和/或种族）; 与移植物相关联的一个或多个变量（例如，移植物是从活体供体或尸体获得的以及缺血时间）; 和与供体相关联的变量（例如，捐赠者的年龄和/或种族）。可以评估的基因包括介导炎症，免疫激活和细胞死亡的编码剂（我们可以将这些基因称为“炎症”，“免疫”或“细胞保护”）。令人吃惊的是，即使在进行移植后（例如血管吻合术和组织再灌注后不久），基因表达水平也能够预测DGF，AR的发生以及晚期移植物功能的质量。我们还发现移植时可用的临床参数与移植物健康状况有关，可以与基因表达相结合，以评估患者的不良结局风险。

8. 发明授权

US06869929B2 Use of transcription factors for treating inflammation and other diseases 失效
标题翻译：使用转录因子治疗炎症等疾病
公开(公告)号：US06869929B2
公开(公告)日：2005-03-22
申请号：US10393905
申请日：2003-03-20
申请人： Peter Oettgen , Towia Libermann , Mary Goldring
发明人： Peter Oettgen , Towia Libermann , Mary Goldring
IPC分类号： A61K31/00 , A61K38/10 , A61K45/06 , G01N33/50 , G01N33/564 , G01N33/68 , C07K14/00
CPC分类号： G01N33/5008 , A61K31/00 , A61K38/10 , A61K45/06 , G01N33/502 , G01N33/5023 , G01N33/5044 , G01N33/5061 , G01N33/5091 , G01N33/564 , G01N33/6863 , G01N33/6872 , G01N2333/4703 , G01N2500/10
摘要： The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.
摘要翻译：本发明提供一种治疗哺乳动物炎症的方法，包括改变参与炎症反应的转录因子的活性。本发明还涉及使用转录因子筛选能够减少炎症的化合物。本发明还涉及转录因子在诊断哺乳动物组织中炎性疾病的存在的方法中的用途以及监测哺乳动物组织中炎症性疾病的治疗方法。

9. 发明授权

US06960444B2 Transcriptional mediators of blood vessel development and endothelial differentiation 失效
标题翻译：血管发育和内皮细胞分化的转录调节因子
公开(公告)号：US06960444B2
公开(公告)日：2005-11-01
申请号：US10446468
申请日：2003-05-28
申请人： Peter Oettgen , Towia Libermann
发明人： Peter Oettgen , Towia Libermann
IPC分类号： C12N15/09 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/53 , A61K45/00 , A61K48/00 , A61P1/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07K14/465 , C07K14/47 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/12 , C12P21/02 , C12Q1/68 , G01N33/53 , C07K14/00
CPC分类号： C07K14/4705 , A61K38/00 , A61K48/00 , C07K14/465
摘要： This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor, which activates vascular specific genes. More particularly, the transcription factor comprises ELF-1, and transcription factors that are homologous to ELF-1. The invention further relates to methods of screening for compounds that affect the activity of these transcription factors, and therefore, affect the development of blood vessels and/or endothelial cell differentiation. The invention also relates to methods of using these compounds to treat diseases, or symptoms of diseases, by either increasing or decreasing blood vessel development and/or endothelial cell differentiation.
摘要翻译：本发明涉及调节哺乳动物血管发育和/或内皮细胞分化的方法，包括改变激活血管特异性基因的Ets转录因子的活性。更具体地，转录因子包括ELF-1和与ELF-1同源的转录因子。本发明还涉及筛选影响这些转录因子活性的化合物的方法，因此影响血管和/或内皮细胞分化的发展。本发明还涉及通过增加或减少血管发育和/或内皮细胞分化来使用这些化合物来治疗疾病或疾病症状的方法。

10. 发明授权

US5958403A Methods and compounds for prevention of graft rejection 失效
标题翻译：防止移植物排斥反应的方法和化合物
公开(公告)号：US5958403A
公开(公告)日：1999-09-28
申请号：US273402
申请日：1994-07-11
申请人： Terry Strom , Towia Libermann
发明人： Terry Strom , Towia Libermann
IPC分类号： A61K38/00 , A61K48/00 , A61P37/06 , C07K14/47 , C07K14/495 , C07K14/54 , C12N15/63
CPC分类号： C07K14/4713 , C07K14/4703 , C07K14/495 , C07K14/54 , A61K38/00 , A61K48/00
摘要： Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
摘要翻译：公开了局部免疫抑制的方法，其可用于预防移植物排斥或防止由于自身免疫性疾病引起的组织破坏。还公开了由克隆的无能T细胞分泌的蛋白抑制因子，阻断白细胞介素2（IL-2）刺激的T细胞增殖，具有10至30千道尔顿的表观分子量，可以通过加热至65 15分钟，体外阻断白细胞介素4（IL-4）刺激的T细胞增殖，对T细胞无细胞毒性，并且不抑制T细胞体外IL-2的产生。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式